Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (MARC-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01266837
Recruitment Status : Completed
First Posted : December 24, 2010
Last Update Posted : November 14, 2017
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
iOMEDICO AG